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Abstract
Transposable elements can be viewed as natural DNA transfer vehicles that, similar to integrating viruses, are cap-
able of efficient genomic insertion. The mobility of class II transposable elements (DNA transposons) can be con-
trolled by conditionally providing the transposase component of the transposition reaction. Thus, a DNA of interest
(be it a fluorescent marker, a small hairpin (sh)RNA expression cassette, a mutagenic gene trap or a therapeutic
gene construct) cloned between the inverted repeat sequences of a transposon-based vector can be used for
stable genomic insertion in a regulated and highly efficient manner. This methodological paradigm opened up a
number of avenues for genome manipulations in vertebrates, including transgenesis for the generation of trans-
genic cells in tissue culture, the production of germline transgenic animals for basic and applied research, forward
genetic screens for functional gene annotation in model species, and therapy of genetic disorders in humans.
Sleeping Beauty (SB) was the first transposon shown to be capable of gene transfer in vertebrate cells, and recent
results confirm that SB supports a full spectrum of genetic engineering including transgenesis, insertional mutagen-
esis, and therapeutic somatic gene transfer both ex vivo and in vivo. The first clinical application of the SB system
will help to validate both the safety and efficacy of this approach. In this review, we describe the major transposon
systems currently available (with special emphasis on SB), discuss the various parameters and considerations perti-
nent to their experimental use, and highlight the state of the art in transposon technology in diverse genetic
applications.
Transposons as genetic tools
DNA transposons are discrete pieces of DNA with the
ability to change their positions within the genome via a
‘cut and paste’ mechanism called transposition. In nature,
these elements exist as single units containing the trans-
posase gene flanked by terminal inverted repeats (TIRs)
that carry transposase binding sites (Figure 1A). How-
ever, under laboratory conditions, it is possible to use
transposons as bi-component systems, in which virtually
any DNA sequence of interest can be placed between the
transposon TIRs and mobilized by trans-supplementing
the transposase in the form of an expression plasmid
(Figure 1B) or mRNA synthesized in vitro.I nt h et r a n s -
position process, the transposase enzyme mediates the
excision of the element from its donor plasmid, followed
by reintegration of the transposon into a chromosomal
locus (Figure 1C). This feature makes transposons nat-
ural and easily controllable DNA delivery vehicles that
can be used as tools for versatile applications, ranging
from somatic and germline transgenesis to functional
genomics and gene therapy (Figure 2).
Transposons have been successfully used in plants and
in invertebrate animal models, including Arabidopsis,r i c e ,
Caenorhabditis elegans [1-3] and Drosophila [4-6] for
transgenesis and insertional mutagenesis, but until
recently, there was no known transposon that was suffi-
ciently active to be tailored as a tool for such purposes in
vertebrates. This is because transposons tend to have lim-
itations with respect to the species in which they can
jump. In 1997, the Sleeping Beauty (SB) transposon system
was engineered by molecular reconstruction of an ancient,
inactive Tc1/mariner-type transposon found in several fish
genomes [7]. This newly reactivated element allowed
highly efficient transposition-mediated gene transfer in
major vertebrate model species without the potential risk
of cross-mobilization of endogenous transposon copies in
host genomes. This is because the genomes of major mod-
els lack endogenous transposon sequences with sufficient
sequence similarity for mobilization by an exogenously
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used as a tool for genetic modifications of a wide variety of
vertebrate cell lines and species including humans [8-10].
During the past decade, other elements have been
shown to catalyze efficient transposition in vertebrate
model organisms. For example, the insect elements pig-
gyBac [11,12] and Minos [13,14] catalyze efficient trans-
position in mammalian cells. Minos was also shown to
be active in the basal chordate Ciona intestinalis [15].
Moreover, the reconstructed amphibian element Frog
Prince [16], the reconstructed human Hsmar1 element
[17], the reconstructed zebrafish transposon Harbin-
ger3_DR [18], and the Tol1 [19] and Tol2 [20] elements
isolated from the medaka fish have been found to be
active in vertebrate species. Passport, a Tc1-family trans-
poson isolated from a fish (Pleuronectes platessa), is
active in a variety of vertebrate cells [21], and the Ac/Ds
transposon originally discovered in maize by McClintock
undergoes efficient transposition in zebrafish embryos
[22]. Thus, the piggyBac, Minos and Ac/Ds elements
appear to have a significantly wider possible host range
than most other transposons. The basic criteria for the
applicability of a transposon in any given model organ-
ism are 1) a sufficient level of transpositional activity in
the given species, and 2) target site selection properties
of the transposon, which are discussed below.
Hyperactive transposon systems
In evolutionary terms, the SB transposon represents a
successful element that was able to colonize several fish
genomes millions of years ago [7]. However, even suc-
cessful transposons have not been selected for the
Figure 1 General organization and use of class II transposable elements as gene vectors.( A) Autonomous transposable elements consist
of terminal inverted repeats (TIR; black arrows) that flank the transposase gene. (B) Bi-component transposon vector system for delivering
transgenes that are maintained in plasmids. One component contains a DNA of interest between the transposon TIRs carried by a plasmid
vector, whereas the other component is a transposase expression plasmid, in which the black arrow represents the promoter driving expression
of the transposase. (C) The transposon carrying a DNA of interest is excised from the donor plasmid and is integrated at a chromosomal site by
the transposase.
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viruses, they have to coexist with their hosts and, conse-
quently, there is strong selective pressure to avoid inser-
tional mutagenesis of essential genes. Indeed, although
the resurrected SB element was sufficiently active to be
mobilized in vertebrate cells, its relatively limited trans-
positional activity still presented a bottleneck for some
applications. For example, requirements for transfection
of primary cells and other hard-to-transfect cell types,
or for remobilization of transposons from chromoso-
mally resident single-copy donor sites, demanded an
enzyme with more robust activity. Thus, enhancing
transpositional activity has been one of the main targets
for transposon vector development. To date, almost
every single amino acid in the SB transposase has been
changed in an attempt to increase its activity. Three
main strategies have been applied to derive hyperactive
mutants of the SB transposase: ‘importing’ amino acids
and small blocks of amino acids from related transpo-
sases [23-25], systematic alanine scanning [26], and
rational replacement of selected amino acid residues
[24]. Together, these studies have yielded several, single
amino acid replacements, each resulting in a relatively
modest increase in transpositional activities. Unfortu-
nately, the hyperactivity of most of the SB transposase
mutants selected in immortalized cell lines did not
translate to efficient stable gene transfer in primary cells
in vivo [25,26].
Earlier studies established that certain combinations of
amino acid replacements, each leading to hyperactivity,
can yield a further enhancement in transpositional activ-
ity of the SB transposase [23-26], but guessing the cor-
rect combinations of variants out of the millions that
a r ep o s s i b l ei sl i k ef i n d i n gt h ec o r r e c tc o m b i n a t i o n so f
numbers in a lottery. A high-throughput, PCR-based,
DNA-shuffling strategy and screening of 2000 gene
Figure 2 Broad applicability of transposon-based gene vectors in vertebrate genetics.
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that was 100-fold more potent in chromosomal insertion
of a transgene than the originally reconstructed protein
[27]. The use of SB100X demonstrated that it is possible
to establish a transposon-based, non-viral vector system
t h a ti sc a p a b l eo fs t a b l eg e n et r a n s f e rc o u p l e dw i t h
long-term gene expression at an efficiency comparable
with that of viral strategies [27]. Thus, the hyperactive
SB100X transposase holds great promise of offering
broad utility in gene therapy and functional genomics.
Integration site preference
The insertion pattern of most transposons is nonran-
dom, showing characteristic preferences for insertion
sites at the primary DNA sequence level, and ‘hotspots’
and ‘cold regions’ on a genome-wide scale. For example,
for the primary DNA sequence, the Tol2 element does
not appear to exhibit a pronounced preference for any
sequence for insertion [28]. By contrast, the Harbin-
ger3_DR transposon is highly specialized to integrate
into the palindromic AAACACCWGGTCTTT consen-
sus sequence [18], the piggyBac transposon targets the
sequence TTAA, and all Tc1/mariner transposons,
including SB, Frog Prince, Minos and Hsmar1,t a r g e t
their integration into TA dinucleotides. In the case of
SB, this preference has been studied in detail, and palin-
dromic AT repeats found to be the preferred sites for
integration [29]. However, computational analyses
revealed that target selection is determined primarily at
the DNA structure level, not by specific base-pair inter-
actions. For example, protein-induced deformability was
shown to be associated with preferred SB insertion sites,
whereas piggyBac and Tol2 integration sites lack such
consistent, clear-cut structural patterns [30,31]. This
suggested that integrations of SB will occur into any
DNA available, depending on these preferences only,
but this is not the case. In the context of chromatin,
Tc1/mariner elements have no or weak preference for
transcription units, the 5’ regulatory regions are not
favored, and most hits in genes are localized within
introns [29,32]. By contrast, piggyBac shows a greater
propensity to integrate into transcription units, with a
preference for insertion around transcription start sites
[12,33-35], and the Tol2 transposon also shows a pro-
nounced preference for integration close to transcrip-
tional start sites [28]. This control of integration at the
chromatin level is poorly understood. One possible
explanation for this is the interaction of the transposase
with unknown, chromatin-associated factors. Supporting
this hypothesis, it has been shown that a host-encoded
protein, lens epithelium derived growth factor (LEDGF),
is involved in directing integration of human immuno-
deficiency virus (HIV) into active genes [36]. Taken
together, the preferences of particular elements to
integrate into expressed genes versus non-coding DNA,
and their preferences for integration sites within genes
are expected to be substantially different.
Integration site preference can greatly influence the
utility of transposon vectors for different applications.
For example, human gene therapy protocols require
application of transposon vectors showing the least pre-
ference for target genes, for obvious safety reasons. The
SB system (which shows close-to-random insertion site
distribution) appears to best satisfy these needs, whereas
the piggyBac and Tol2 systems (which prefer genes and
their upstream regulatory regions for insertion) appear
to be less favorable for potential therapeutic applica-
tions. Nevertheless, a systematic assessment of potential
genotoxic effects associated with genomic integration of
transposon vectors will need to be performed either in
cell-based assays and/or in animal models to provide
clinically relevant data.
Unlike in therapeutic applications, hitting genes by
insertional elements is the goal with forward mutagen-
esis screens. However, the insertional biases associated
with vector systems represent the main limitation to full
genome coverage with individual transposon-based vec-
tors. Thus, in this respect, the utility of transposons for
mutagenesis is greatly enhanced by the availability of
multiple alternative vector systems with distinct prefer-
ences for insertion, such as SB, Tol2 and piggyBac.
Indeed, the propensity of Tol2 to insert close to tran-
scriptional start sites of genes might be particularly
advantageous for enhancer trapping [37,38], while the
propensity of piggyBac to insert into transcription units
supports genome-wide mutagenesis with gene trap cas-
settes [39].
Local hopping
’Local hopping’ describes a phenomenon of chromoso-
mal transposition in which transposons have a prefer-
ence for landing into cis-linked sites in the vicinity of
the donor locus. Local hopping seems to be a shared
feature of ‘cut and paste’ transposons. However, the
actual extent of hopping to linked chromosomal sites
and the interval of local transposition varies. For exam-
ple, the P-element transposon of Drosophila prefers to
insert within ~100 kb of the donor site at a rate ~50-
fold higher than in regions outside that interval [40].
Similarly, in germline mutagenesis screens in mice using
SB, 30-80% of the transposons re-insert locally on either
side of the transposon donor locus [41-43]. In contrast
to the P-element, SB seems to have a much larger local
transposition interval between 5 and 15 Mb [42].
The local hopping feature not only differs between dif-
ferent transposons, but a given transposon may show
great variations in local hops in different hosts, and in
different donor loci even in the same host. For example,
Ivics and Izsvák Mobile DNA 2010, 1:25
http://www.mobilednajournal.com/content/1/1/25
Page 4 of 15about 50-60% of the reinserted Ac elements were found
to be distributed within a 5-cM distance of the donor
site in maize [44,45], and the frequency of local hopping
greatly varies in Arabidopsis and tobacco, depending on
the chromosomal location of the donor site [46-48].
Moreover, local hopping of the Ac element in tomato
seems overall to be less prevalent than in maize [49,50],
and there are species-specific differences in its tendency
for local hopping out of different transposon donor loci
[51]. This variation in local hopping of the same ele-
ment could possibly be explained by varying affinity of
the transposase to unknown, chromatin-associated fac-
tors in different hosts [52].
Local hopping can play a significant role in mutagen-
esis using chromosomally resident transposons. In prac-
tical terms, local hopping limits the chromosomal
regions accessible to a transposon jumping out of a
given chromosomal site [53]. To circumvent this limita-
tion, establishing numerous ‘launch pads’ to initiate
transposition out of different loci can be a viable strat-
egy to increase coverage of gene mutations. On the
other hand, local hopping can be useful for saturation
mutagenesis within limited chromosomal regions.
Transposons and functional genomics
The post-genomic era presented the scientific community
with the new challenge of functional annotation of every
gene and identification of elaborate genetic networks.
Diverse methods have been employed to address this task,
including mutational analysis, which proved to be one of
the most direct ways to decipher gene functions. There
are versatile strategies for creating mutations, including
insertional mutagenesis by discrete pieces of foreign DNA,
which has the advantage that the inserted DNA fragment
can serve as a molecular tag that allows rapid, usually
PCR-based, identification of the mutated allele. Because
the function of the gene in which the insertion has
occurred is often disturbed, such loss-of-function inser-
tional mutagenesis is frequently followed by functional
analysis of mutant phenotypes. In many instances, retro-
viral vectors were used to introduce mutagenic cassettes
into genomes, but their chromosomal insertion bias does
not allow full coverage of genes [54]. The random integra-
tion pattern of the SB transposon, combined with its abil-
ity to efficiently integrate versatile transgene cassettes into
chromosomes established this system as an extremely use-
ful tool for insertional mutagenesis in both embryonic
stem cells (ESCs) [34,55] and in somatic [56,57] and germ-
line tissues [41,42,53,58-63] in animal models (Figure 2).
There are several types of mutagenic cassettes that can be
efficiently combined with transposon-based gene delivery
for insertional mutagenesis. 5’ gene-trap cassettes include
splice acceptors and polyadenylation sequences so that
transcription of genes can be disrupted upon vector
insertion into introns (Figure 3A) [54]. Often, such cas-
settes are also equipped with a reporter gene (usually, a
fluorescent protein, b-galactosidase or antibiotic resis-
tance) whose expression is dependent on correct splicing
between exons of the trapped gene and the splice acceptor
site carried by the transposon vector [64,65].
Insertional mutagenesis can be applied to cultured,
germline-competent stem cells including ESCs and sper-
matogonial stem cells (SSCs) [39,66]. One advantage of
this approach is the ability to perform preselection of
modified ESC clones before generating mutant animals,
and to differentiate selected clones into many different
tissue types in vitro. It is possible to perform large-scale,
transposon-based, insertional mutagenesis screens in
ESCs and SSCs by simply transfecting or electroporating
transposon donor and transposase expression plasmids
into the cells. The amounts of the delivered plasmids can
be adjusted to obtain the desired insertion frequencies
per cell. In addition, transposons can also be remobilized
from chromosomally resident loci and reintegrated some-
where else in the genome by transiently providing the
transposase source; such excision-re-integration events
can be monitored using double selection systems, in
which excision activates the first and re-integration acti-
vates the second selection marker [43].
Because several aspects of physiology in rats have
evolved to be more similar to humans than to mice, it
would be desirable to use rat models in the process of
functionally annotating the human genome by identifying
the causative relationships between genes and disease phe-
notypes. As an important step towards this goal, an
approach of establishing SB transposon-mediated inser-
tional mutagenesis in rat SSCs was recently reported [66].
SB transposition can be used to tag and simultaneously
mutate thousands of genes in culture, using gene-trap cas-
settes. Importantly, culture conditions maintain the poten-
tial of genetically manipulated SSCs to produce viable
sperm cells. In that study, spermatogonial clones were
transplanted to repopulate the testes of sterilized, wild-
type recipient male rats. The stem cell genome was then
passed on to transgenic offspring upon crossing of the
recipient males with wild-type females (Figure 4).
Although transposition events in a given target gene occur
by chance, the tissue culture conditions allow screening
for a large number of events. Transposition-mediated gene
insertion and cell culture conditions thus allow generation
of libraries of gene knockouts in rat SSCs (Figure 4). This
technology has the potential to develop powerful genomic
tools for use in the rat, offering the opportunity to create a
bridge between physiology and genomics.
Another method in which transposons are used
for insertional mutagenesis in animal models employs
a ‘jump-starter and mutator’ scheme [42,58,61]. In
this arrangement, mutator transgenic lines carry SB
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multicopy concatemers, whereas a jump-starter line
expresses the transposase preferentially in the male germ-
line [41,64]. Crossing of the two lines results in transposi-
tion in the germline of the F1 double-transgenic males,
which are then repeatedly crossed with wild-type females
to segregate the transposition events that occurred in their
sperm cells to separate F2 animals. In the mouse system, a
single sperm cell of an F1 male contains, on average,
two transposon insertions [58], and up to 90% of the
F2 progeny can carry transposon insertions [61]. The
applicability of this approach has been demonstrated by
the identification of mouse genes with either ubiquitous or
tissue-specific expression patterns [42,64,67,68]. Recently,
a similar system for SB insertional mutagenesis was also
established in rats [62,63].
One cautionary note of launching transposition out of
transposon arrays is that recombination between newly
transposed transposon copies and the donor concatemer
could lead to unwanted genomic rearrangements, as
observed by Geurts et al. [68]. The most likely explana-
tion for the rearrangements is that transposition out of
Figure 3 Major types of expression and mutagenic cassettes delivered by transposon vectors for versatile applications.( A) A gene-trap
transposon contains a splice acceptor (SA) sequence followed by a promoterless reporter gene such as lacZ and a poly-A (pA) signal. The
reporter gene is expressed only when its transcription is initiated from the promoter of a disrupted, actively transcribed endogenous
transcription unit. Therefore, the expression pattern of the transposon reporter reflects that of the endogenous gene harboring the transposon
insertion. (B) Oncogene-trap transposons include a strong viral promoter/enhancer long terminal repeat (LTR) sequence that can drive
transcription toward the outside of the transposon and a splice donor (SD) sequence, so that forced transcription and splicing to downstream
exons will result in overexpression of a product of a gene into which the transposon has inserted. Classic oncogene trap vectors also contain SA
and pA sites to induce gene truncations that have dominant phenotypes. (C) Knockdown expression cassette including a polymerase (Pol) II
promoter that drives expression of a marker gene and a Pol III promoter that drives expression of a short hairpin (sh)RNA. (D) A typical
therapeutic expression cassette contains a ubiquitous or tissue-specific enhancer/Pol II promoter that drives expression of a therapeutic gene. To
enhance the safety of such a vector, the expression cassette might be flanked by insulator elements that will block transactivation of
endogenous promoters by the transposon insertion, and simultaneously protect the expression of the therapeutic gene from position effects.
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linked either in cis (in the case of local hops) or in trans
(in the case of transposition onto other chromosomes).
However, because some transposon copies remain at the
original donor locus, transposase can recombine chro-
mosomal sequences that are located between the indivi-
dual transposon units by hybrid element transposition
(that is, the end of one transposon pairs with the oppo-
site end of another transposon at a different location)
[69], leading to deletions and translocations. Such chro-
mosomal rearrangements are unlikely to occur if a sin-
gle-copy donor is used. Thus, transposon systems
sufficiently active for efficient transposition out of
single-copy donors might eliminate the need for conca-
temeric donor sites in animal breeding schemes.
Indeed, the Tol2 element was demonstrated to show
transposition at reasonable efficiencies when launched
from singly-copy donor sites in transgenic zebrafish
[70]. In this context, the newly developed SB100X
hyperactive system might also prove useful in future
genetic screens.
Forward genetic screens do not necessarily need to
depend on the breeding scheme described above; in
some cases, a reasonable throughput in generation of
transposon insertion mutants can be achieved by intro-
ducing the mutagenic transposon into individual ani-
mals, such as in zebrafish. A gene trap mutagenesis
screen was recently employed to uncover genetic deter-
minants of nicotine response in zebrafish, through a
behavioral genetic screening paradigm [71]. Using stan-
dard transposase-mediated transgenesis protocols, Tol2-
based mutagenic vectors were co-injected into early
Figure 4 Generation of knockout rats by insertional mutagenesis with gene trap transposons in spermatogonial stem cells. Cultured
stem cells are transfected with gene trap transposon and transposase constructs that will lead to thousands of transposon insertions covering all
chromosomes. Those cells in which insertions have occurred in expressed genes can be selected based on activation of the gene trap marker,
and the insertion sites can be mapped. Cell clones or polyclonal insertion libraries can be transplanted into the testes of sterile males, in which
the spermatogonial step cells will undergo spermatogenesis. These transplanted males are crossed with wild-type females to pass the insertions
through the germline and generate transgenic/knockout animals.
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founder animals, which then underwent two successive
rounds of crossing to generate homozygous mutant ani-
mals. Segregation of mutant animals from wild-type sib-
lings was carried out using fluorescent reporters built
into the gene trap cassettes. After profiling nicotine
response in mutant versus wild-type fish, two mutants
were identified out of a total of 102 fish lines screened
[71]. This study emphasizes the utility of transposons
for the discovery and functional annotation of genes
relevant to human health in forward, phenotype-driven
genetic screens in model species.
Transposon-based screens for cancer gene discovery
To induce gain-of-function mutations, transposon vec-
tors can be equipped with oncogene trap cassettes that
contain strong viral enhancers/promoters that can drive
transcription outwards from the vector, thereby leading
to overexpression of a full-length or truncated protein
product of the trapped gene, as well as splice acceptor
and polyA sites that lead to gene truncation with domi-
nant phenotypes (Figure 3B) [9,72]. SB vectors harboring
oncogene traps have been successfully used in large-scale
cancer gene discovery screens in experimental animals
(Figure 5) [10,73,74]. In these studies, SB transposons
were somatically mobilized from donor chromosomal
concatemers, which contained either low (25) [56] or
high (150-350) [57] numbers of the oncogene trap trans-
poson. Dominant mutations in somatic tissues of double
transgenic mice carrying a transposase source and the
mutagenic transposons resulted in the generation of
experimental tumors in cancer-predisposed [56] and
Figure 5 Transposon-mediated cancer gene discovery screen.B r e e d i n go f‘jumpstarter’ and ‘mutator’ stocks induces transposition in the soma of
double-transgenic animals (’oncomice’). In the case of tissue-specific screens, a third genotype containing a tissue-specific Cre allele has to be crossed
in to the backgrounds. The crosses can be made either in wild-type or in specific cancer-predisposed genetic backgrounds. Transposition in somatic
cells leads to random insertional mutations, and animals are monitored for tumor development. Transposon insertions are cloned from genomic DNA
isolated from tumor samples, and are subsequently mapped and the mutagenized genes identified. Those genes repeatedly mutated in multiple,
independent tumors are designated as common insertion sites (CIS). These candidate cancer genes are then functionally validated.
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demonstrated that a combination of low-copy oncogene
trap lines with the SB11 transposase (an early-generation
hyperactive SB variant) expressed from the Rosa26 locus
could achieve whole-body transposon mobilization at
rates sufficient to promote penetrant tumorogenesis
without complications of embryonic lethality or genomic
instability [75]. Thus, this approach can be successfully
employed not only to identify novel cancer genes, but
also combinations of cancer genes that act together to
transform a cell.
Current efforts are concentrating on customized, tis-
sue-specific screens for cancer development studies. The
strategies employed to achieve this goal focus on estab-
lishing mouse lines that either conditionally express the
transposase from tissue-specific promoters, or rely on
generation of Cre recombinase-inducible transposase
alleles that can be used in conjunction with mice that
express Cre in a tissue-specific manner [76-78]. For
example, this approach was addressed by Dupuy and co-
workers [72], who were able to experimentally modify
the spectrum of tumors by creating a Cre-inducible SB
transposase allele (RosaSBase
LsL). With this strategy,
they managed to overcome the obstacle of high embryo-
nic lethality associated with ubiquitous SB transposase
expression in the presence of the pT2/Onc2 oncogene
trap [76,79], and to generate a model of germinal center
B-cell lymphoma. They achieved this by activating SB
transposase expression with an AidCre allele that drove
Cre-mediated recombination in germinal center B-cells.
In another approach, ubiquituous expression of the SB
transposase was combined with the novel T2/Onc3
oncogene trap transposon vector. In that study, the
MSCV (mouse stem cell virus) 5’ long terminal repeat
that was previously used to drive oncogene expression
was replaced by the ubiquitously active CAGGS promo-
ter, resulting in removal of the bias towards inducing
mostly lymphomas and in reducing embryonic lethality.
This strategy emphasizes that the change in the design
of the mutagenic transposon (e.g. promoter choice) can
have profound effects on the tumor types induced by
transposition. Notably, this approach resulted in produc-
tion of nearly 200 independent tumors of more than 20
types, and identification of novel, candidate cancer
genes, suggesting that the combination of tissue-specific
promoters and inducible transposase alleles could pro-
vide a fine mechanism of control in tumorogenesis
studies.
Transposons as vectors for stable transgene
integration and expression
The classic approaches to stable expression of foreign
genes in vertebrates rely on physical methods of deliver-
ing gene constructs into cultured cells, such as
transfection, electroporation and sonoporation, or micro-
injection into oocytes or fertilized eggs to generate germ-
line transgenic animals. The main drawbacks of these
approaches are the low rates of genomic integration and
the unstable expression of the chromosomally integrated
gene construct, which is believed to be associated with
the phenomenon of concatemerization of the injected
DNA before genomic integration [80]. Another particular
problem in transgenic animals is that founders that
develop from the injected oocytes or eggs are predomi-
nantly mosaic for the transgene, because integration
generally occurs relatively late during embryonic devel-
opment. In principle, all of these drawbacks can be cir-
cumvented by transposition-mediated gene delivery, as it
can increase the efficiency of chromosomal integration
and facilitates single-copy insertion events. Single units
of expression cassettes are presumably less prone to
transgene silencing than are the concatemeric insertions
created by classic methods.
Transposon-based technologies can be exploited for
gene transfer in cultured cells and in primary cell types,
including stem cells (Figure 2). For example, transposons
can be harnessed to integrate plasmid-based shRNA
expression cassettes into chromosomes to obtain stable
knockdown cell lines by RNA interference (Figure 3C)
[81]. Such technologies have been evaluated as a poten-
tial approach to the therapy of acquired immunodefi-
ciency syndrome by stable RNA interference with SB
vectors knocking down the CCR5 and CXCR4 cell sur-
face co-receptors that are required for viral entry as a
f i r s ts t e pt oc o n f e rr e s i s t a n c et oH I V[ 8 2 ] .B o t ht h eSB
and the piggyBac systems were shown to support efficient
transposition in mouse [33,43] and human [83,84] ESCs.
In a recent, elegant study, piggyBac-derived transgene
vectors were introduced into human ESCs for the pur-
pose of driving ESC differentiation toward a specific cell
type [84]. The vectors included loss-of-function shRNA
expression cassettes that could simultaneously knock
down the expression of pluripotency genes and of genes
that contribute to endodermal and mesodermal differen-
tiation, plus a gain-of-function construct expressing Sox1
to direct differentiation towards neuroectoderm. What
makes such complex gene-transfer experiments possible
is the observation that several transgene constructs main-
tained on separate transposon vectors can be delivered
simultaneously in ‘multiplex’ transposition reactions, in
which the different constructs are simply mixed together
and cotransfected into cells [85].
The recent discovery of induced pluripotent stem cells
(iPSCs) by the expression of four key genes (Oct4, Sox2,
Klf4 and c-Myc) in differentiated somatic cells
holds enormous promise for future regenerative medicine
[86]. Transposons are attractive vehicles for reversible
production of iPSCs, because the excision step of the
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expression of the transposase offers removal of the trans-
genes after completion of reprogramming, allowing
subsequent differentiation of the iPSCs into various
lineages in vitro [87]. Transposition-mediated generation
of mouse and human iPSCs, and removal of the repro-
gramming factors from the pluripotent cells have already
been achieved by the piggyBac system [88]. What makes
piggyBac transposons especially attractive vectors for the
production of transgene-free iPSCs is a special feature of
these transposons: excision fully restores the sequence of
the original wild-type locus [89], thereby allowing trace-
less removal of transgenes from the genome.
In vivo, co-injection of engineered transposons with
transposase mRNA into fertilized oocytes can facilitate
early integration events that potentiate successful trans-
mission of the transgene through the germline to the
next generation (Figure 2). This method has been
employed to generate transgenic zebrafish with Tc3 [90],
Mos1 [91], Tol2 [20] and SB [92]; transgenic Xenopus
with SB [93] and Tol2 [94]; and transgenic mice with SB
[27,95-97], piggyBac [11] and Tol2 [98]. In this context,
an important step towards transgenesis with bacterial
artificial chromosomes (BACs) has been made by the
delivery of a ~70-kb BAC construct into zebrafish and
mouse embryos with Tol2 [99]. Thus, transposons can
evidently be used to stably deliver large transgene con-
structs together with complex regulatory regions, with-
out the complications of DNA rearrangements and
silencing associated with classic methods.
Any transgene vector system should provide long-term
expression of transgenes. Transgenes delivered by non-
viral approaches often form long, repeated arrays (conca-
temers) that are targets for transcriptional silencing by
heterochromatin formation. In addition, long-term
expression of transgenes delivered by retroviruses has
been shown to be compromised by transcriptional silen-
cing [100]. It was recently shown that the zinc finger pro-
tein ZFP809 bridges the integrated proviral DNA
of the murine leukaemia virus and the tripartite motif-
containing 28 transcriptional co-repressor in embryonic
stem cells [101]. Thus, sequence elements in the vector
itself can predispose the cargo for silencing. The cut and
paste mechanism of DNA transposition results in a single
copy of the transgene per insertion locus, thus concate-
mer-induced gene silencing is unlikely to be an issue
with transposition-mediated gene transfer. Indeed, Gra-
bundzija et al. found that transposon insertions delivered
by the SB, Tol2 and piggyBac systems only rarely (<4% of
all insertions) undergo silencing in HeLa cells [28].
Furthermore, stable transgene expression observed in
hundreds of independent insertions in this study suggests
that these three transposon systems rarely target hetero-
chromatic chromosomal regions for insertion, and that it
is unlikely that certain sequence motifs in the transposon
vectors are recognized by mediators of silencing in the
cell. An additional factor that may provoke transgene
silencing is the cargo DNA, particularly the type of pro-
moter used to drive expression of the gene of interest.
Indeed, it was previously shown that transgene constructs
delivered into mouse cells using SB transposition can be
subject to epigenetic regulation by CpG methylation and
that a determinant of epigenetic modifications of the
integrating transposon vector is the cargo transgene con-
struct, with the promoter playing a major role [102].
However, with careful promoter choice, several studies
have established that SB-mediated transposition provides
long-term expression in vivo. For example, stable trans-
gene expression from SB vectors was seen in mice after
gene delivery in the liver [103-106], lung [107,108], brain
[109] and blood after hematopoietic reconstitution
in vivo [27,110]. Thus, although our understanding of all
the factors that will ultimately determine the expressional
fate of an integrated transposon is still rudimentary, it
appears that transposon vectors have the capacity to pro-
vide long-term expression of transgenes both in vitro and
in vivo.
Transposons as vectors for gene therapy
Considerable effort has been devoted to the develop-
ment of gene delivery strategies for the treatment of
inherited and acquired disorders in humans. A desirable
gene therapy approach should 1) achieve delivery of
therapeutic genes at high efficiency specifically into the
relevant cells, 2) be adaptable to changing needs in
terms of vector design, 3) minimize the risk of genotoxi-
city, and 4) be cost-effective.
Adapting viruses for gene transfer is a popular approach;
for example, g-retroviral and lentiviral vectors are efficient
at integrating foreign DNA into the chromosomes of
transduced cells and have enormous potential for lifelong
gene expression [111]. A major concern of using retroviral
vectors is the potential for mutagenic effects at the sites of
genomic integration [112-114]. Indeed, insertional muta-
genesis has been observed in clinical trials using a retro-
viral vector for gene therapy of X-linked severe combined
immunodeficiency [112,114,115]. The clinical use of retro-
viral vectors can be curtailed because of the limited size of
the payload, as multiple or large transgenes compromise
the efficiency of viral reverse transcription and packaging.
Finally, regulatory issues and the high costs associated
with manufacture of clinical-grade retrovirus hamper their
widespread translation into clinical practice. An ideal ther-
apeutic vector would combine the favorable attributes of
integrating viral vectors (that is, stable chromosomal inser-
tion) while significantly reducing the potential for adverse
events. Transposons could potentially offer such an alter-
native (Figure 2).
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that, owing to stable genomic insertion of expression
cassettes, it can lead to both long-term and efficient
transgene expression in preclinical animal models [116].
Thus, the SB plasmid-based transposon system com-
bines the advantages of viral vectors with those of naked
DNA molecules. However, in contrast to viral vectors,
transposon vectors can be maintained and propagated
as plasmid DNA, which makes them simple and inex-
pensive to manufacture, an important issue for the
implementation of future clinical trials. Further advan-
tages of the SB system include its reduced immunogeni-
city [103], no strict limitation of the size of expression
cassettes [24] and improved safety and toxicity profiles
[87,117-119]. Because the transposition mechanism does
not involve reverse transcription, DNA-based transpo-
son vectors are not prone to incorporating mutations
and can tolerate larger and more complex transgenes,
including those containing repeat DNA motifs. More-
over, the use of SB-based gene delivery eliminates the
risk of rearrangements of the expression cassette that, as
part of a transposing unit of DNA, integrates into chro-
mosomal DNA in an intact form [120]. Compared with
retroviral systems, the SB vectors have an inherently low
enhancer/promoter activity [117,118]. Inserting insulator
sequences flanking the transcription units of the cargo
to prevent accidental trans-activation of promoters of
neighboring genes further increased the safety features
of the SB system (Figure 3D) [117]. Notably, the trans-
posase can be provided as messenger RNA, thereby
reducing the risk of ‘rehopping’ of the transposon-based
vector [96]. Chromosomal integration of SB transposons
is precise and random (see above), and no SB-associated
adverse effects have been reported [116,120,121]. Of
note, a precise integration mechanism, random integra-
tion pattern and negligible promoter/enhancer activity
do not appear to be general features of all recombinase/
transposon systems. For example, integration promoted
by the bacteriophage-derived PhiC31 system was
reported to generate chromosomal rearrangements
[122,123]. The 5’ TIR of the piggyBac transposon exhi-
bits significant promoter activity in mammalian cells
[124], and its genomic integration profile resembles that
of integrating viral vectors [12], as described above.
The past few years have seen a steady growth in interest
in applying the SB system for the treatment of several
conditions including haemophilia A and B [103,104,
106,107,125], junctional epidermolysis bullosa [126], tyro-
sinemia I [127], Huntington disease [128] sickle cell dis-
ease [129], mucopolysaccharidosis [105,130], cancer
[109,131] and type 1 diabetes [132]. In addition, important
steps have been made towards SB-mediated gene transfer
in the lung for potential therapy of a-1-antitrypsin
deficiency, cystic fibrosis and a variety of cardiovascular
diseases [108,133]. Thus, the establishment of non-viral,
integrating vectors has generated considerable interest in
developing efficient and safe vectors for human gene ther-
apy [116,120,134-136].
The SB100X hyperactive transposon system yields effi-
cient stable gene transfer after non-viral gene delivery into
therapeutically relevant primary cell types, including stem
or progenitor cells. For example, the use of the SB100X
system yielded robust gene transfer efficiencies into
human hematopoietic progenitors [27,110], mesenchymal
stem cells, muscle stem/progenitor cells (myoblasts) and
iPSCs [137]. These cells are relevant targets for stem cell
biology and for regenerative medicine and gene- and cell-
based therapies of complex genetic diseases. Importantly,
expression of the SB100X hyperactive transposase did not
adversely influence the differentiation or function of these
adult stem/progenitor cells, nor was there any evidence of
any cytogenetic abnormalities [137]. In the context of
iPSC technology, the ability to coax the differentiation of
pluripotent stem cells into clinically relevant, transplanta-
ble cell types is a key step towards their ultimate use in
clinical applications, especially because undifferentiated
iPSCs pose an intrinsic tumorigenic risk [138]. It was
recently demonstrated that SB transposon-mediated deliv-
ery of the myogenic PAX3 transcription factor into iPSCs
coaxed their differentiation into MyoD+ myogenic pro-
genitors and multinucleated myofibers [137], suggesting
that PAX3 may serve as a myogenic ‘molecular switch’ in
iPSCs, a finding that has implications for cell therapy of
congenital degenerative muscle diseases, including Duch-
enne muscular dystrophy.
The first clinical application of the SB system is cur-
rently ongoing using autologous T cells genetically mod-
ified to redirect specificity for B-lineage malignancies
[139]. Lymphocytes are a suitable initial platform for
testing new gene transfer systems, as there have been
hundreds of infusions of clinical-grade T cells geneti-
cally modified using viral and non-viral approaches
without apparent genotoxicity [140]. The SB transposon
tested in the first human application carries a chimeric
antigen receptor (CAR) to render the T cells specifically
cytotoxic toward CD19-positive lymphoid tumors
[141,142]. The advantage of using the SB system for the
genetic modification of T cells includes the reduced cost
associated with manufacturing of clinical-grade DNA
plasmids compared with recombinant viral vectors. This
is particularly important when one considers that trials
infusing CAR-positive T cells are only now beginning to
demonstrate anti-tumor effects [143,144]. The higher
enzymatic activity of SB100X might enable integration
efficiencies comparable with that of retroviral vectors to
be achieved for next-generation trials.
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Transposon-based technologies have enormous potential
to develop powerful genomic tools with the vision of
creating a bridge between physiology and genetics and
to establish safe and inexpensive protocols for clinical
gene transfer. Simple, plasmid-based vectors matched by
a corresponding transposase source offer an easy and
efficient method for germline transgenesis in laboratory
animals and in large animal species for biotechnology.
Furthermore, it is now both accessible and practical to
generate highly complex libraries of gene knockouts in
model species with a view to establishing new models of
human disease for the annotation of disease pathways
and for therapeutic and pharmaceutical intervention.
The recently developed SB100X hyperactive transposon
system yields highly efficient stable gene transfer after
non-viral gene delivery into therapeutically relevant pri-
mary cell types, including stem cells, and thus may facil-
itate the clinical implementation of ex vivo and in vivo
gene therapies. The next phase of preclinical research
will focus on further refinement in large animal models
to undertake SB-mediated transposition in vivo and to
improve the safety profile of SB vectors by target-
selected transgene integration into genomic ‘safe har-
bors’. Although it remains to be seen whether the first
clinical application of the SB system will result in a ther-
apeutic effect, this trial will help validate the safety of
this approach. The ongoing investigations will certainly
prompt new ideas and new designs to be developed in
this (ever) expanding universe of transposon technolo-
gies for genetic and cell engineering.
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